Gilead Sciences, Inc.
$161.25
+2.05 · +1.29% today
Market open · updated 12:44:26 PM ET
- High
- $160.74 10:55 AM
- Low
- $155.57 8:55 AM
Against the S&P 500 Price change through Oct 27, 2026
GILD+29.61%
S&P 500+12.87%
GILD+32.05%
S&P 500+12.32%
GILD+107.62%
S&P 500+87.41%
GILD+138.25%
S&P 500+69.55%
Key numbers
- Previous close
- $159.20
- Open
- $162.99
- Day's range
- $160.95 – $163.98
- 52-week range
- $114.02 – $163.98
- Volume
- 2.2 million
- Average volume
- 6.6 million
- Market value
- $199.9 billion
- Earnings per share
- -$2.61last 12 months
- Beta
- 0.33moves less than the market
- Dividend
- $3.25 a year · 2.05%
- 50-day average
- $149.97
- 200-day average
- $139.43
Thursday, Oct 29, 2026, after the close.
Analyst price targets and the full financials are in the terminal.
Who Gilead Sciences sells to and competes with From our value chain
Gilead Sciences in the news
No desk stories on GILD yet. When we write about it, the story leads this list.
- Headline3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead24/7 Wall Street · October 28, 2026 at 8:14 AM ET
- HeadlineGilead to Report Q3 Earnings: How Should You Play the Stock Now?Zacks Investment Research · October 27, 2026 at 12:51 PM ET
- HeadlineAhead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research · October 26, 2026 at 10:16 AM ET
- HeadlineGilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · October 22, 2026 at 11:02 AM ET
- HeadlineGilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026Business Wire · October 22, 2026 at 8:00 AM ET
- HeadlineGilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research · October 21, 2026 at 7:01 PM ET
- HeadlineAll You Need to Know About Gilead (GILD) Rating Upgrade to BuyZacks Investment Research · October 19, 2026 at 1:01 PM ET
- HeadlineGilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026Business Wire · October 19, 2026 at 8:00 AM ET
Earnings
Next report: Thursday, Oct 29, 2026, after the close.
Congress trades in GILD
3 purchases and 5 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Aug 10, 2026 | Sep 7, 2026 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Jul 7, 2026 | Aug 12, 2026 |
| Jared MoskowitzHouse · D-Florida | Purchase | $1,001 - $15,000 | May 6, 2026 | Jun 22, 2026 |
| Josh GottheimerHouse · D-New Jersey | Purchase | $1,001 - $15,000 | Jan 27, 2026 | Feb 27, 2026 |
| Val HoyleHouse · D-Oregon | Sale | $1,001 - $15,000 | Sep 23, 2025 | Oct 10, 2025 |
| Marjorie Taylor GreeneHouse | Purchase | $1,001 - $15,000 | Jun 6, 2025 | Jun 19, 2025 |
| Josh GottheimerHouse · D-New Jersey | Sale | $1,001 - $15,000 | May 14, 2025 | Jun 12, 2025 |
| John BoozmanSenate | Sale | $1,001 - $15,000 | Apr 16, 2025 | May 14, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Gilead Sciences
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,000
- Headquarters
- Foster City, California
- Website
- gilead.com
- Listed
- Jan 22, 1992
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.